None listed
Conditions
Interventions
Intervention1: NMN Supplement, 300 mg
NMN Supplement, 600 mg
NMN Supplement, 900 mg: Those who are assigned to 300 mg arm (NMN) will be instructed to take 2 capsules. Those who are assigned to 600 mg
Sponsors
Abinopharm Inc
Eligibility
Inclusion criteria
Inclusion criteria: 1. Male/females of 40 to 65 years of age 2. Body Mass Index (BMI) between 18.5 and 35 kg/m2 3. Able to provide written Informed Consent 4. Able to follow verbal and written study directions 5. Must not be taking or be willing to take any supplements containing any form of niacin for seven days prior to baseline and for the duration of the study. 6. Able to maintain consistent diet and lifestyle habits throughout the study 7. Male and female subjects must be willing to agree to use effective contraceptive methods while on treatment and for 3 months after the completion of study 8. Willing to consume assigned dietary supplements for 2 months
Exclusion criteria
Exclusion criteria: 1. Participants on current use of prescription or over-the-counter nicotinic acid 2. Use of statin drugs 3. Having used any tobacco product or used a recreational drug in the past 6 months 4. Having abnormal screening laboratory test values or other lab test result(s) that would preclude study participation in the judgment of the investigator 5. Documented presence of atherosclerotic disease and/or cardiopulmonary disease 6. History of drug or alcohol abuse 7. History of unstable depression or mental illness within the last 6 months for which the investigator believes could impact the participantââ?¬•s ability to comply with study requirements 8. Unwilling to discontinue use of conventional multivitamin/mineral or other supplements at least two weeks prior to the study start 9. Participating in or planning to begin a weight loss diet during the study period 10. Lifestyle or schedule incompatible with the study protocol 11. Known hypersensitivity to the drug components used during the study 12. Women with positive result for urinary beta human chorionic gonadotropin or gestation period or breastfeeding 13. Other diseases or medications, according to the investigator, that would interfere directly in the results of the study or jeopardize the health of the participant. 14. Currently, or within the past 30 days, enrolled in a different clinical investigation 15. Inability to provide a venous blood sample 16. Unable or unwilling to provide written informed consent for participation in study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Part I To compare the efficacy of NMN as anti-ageing supplementation versus placebo [Time Frame: 2 Months]. To compare the results of telomere test with NMN [Time Frame: 2 Months]. ïâ??· To compare the efficacy of NMN as anti-ageing supplementation [Time Frame: 2 Months].Timepoint: To compare the results of telomere test with NMN [Time Frame: 2 Months]. ïâ??· To compare the efficacy of NMN as anti-ageing supplementation [Time Frame: 2 Months]. | — |
Secondary
| Measure | Time frame |
|---|---|
| To compare the safety and tolerability of the NMN supplementation versus placebo [ Time Frame: 2 Months] (Incidence and type of adverse events) To assess the safety and tolerability of the NMN supplementationTimepoint: 2 months | — |
Countries
India
Contacts
Public ContactSohal Pendse
ProRelix Research (ProRelix Services LLP)
Outcome results
None listed